ACC Concerned Over Reporting of Biomonitori...(inform us about how the chemical was int...),Health

Date:10/23/2007

inform us about how the chemical was introduced, how long it has been there, or whether it poses any health risk what so ever. It would be erroneous to suggest that just because effects can be observed in toxicity studies at high doses of a chemical, that the same effects would occur at much, much lower doses.

The chemical industry recognizes that environmental health issues represent a legitimate concern, and we both recognize and act on our responsibility to help preserve a healthy environment, not only for our own children, but also for future generations. This is a fundamental responsibility we take seriously. ACC members meet this responsibility through compliance with a network of regulatory safeguards including many federal and state laws and through voluntary programs, such as Responsible Care(R), the HPV Challenge and the Voluntary Children's Chemical Evaluation Program Pilot. (VCCEP). Annually, our industry invests over $26 billion on research and innovation, $14 billion on complying with the dozens of federal, and hundreds of state regulations that govern the products, processes and distribution of the products of chemistry, and above that ACC members have invested over $120 million over the past five years in research to evaluate health and environmental impacts of chemicals -- much of which relates to the interpretation of biomonitoring data.

To Learn More About Biomonitoring and Responsible Reporting of Results:

Centers for Disease Control and Prevention

http://www.cdc.gov/exposurereport/

National Academy of Sciences

http://www.nap.edu/catalog.php?record_id=11700

BiomonitoringInfo.Org http://www.biomonitoringinfo.org

http://www.americanchemistr
'/>"/>

SOURCE American Chemistry Council Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis